Thursday, November 05, 2020 8:16:52 PM
Publication from UCSF shows Bionano’s optical genome mapping technology can detect pathogenic variants missed by whole exome sequencing and by chromosomal microarray in patients with rare genetic disorders and may contribute to more patients receiving definitive molecular diagnoses
November 05, 2020 08:00 ET | Source: Bionano Genomics
SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication of a study led by scientists and clinicians from the Institute for Human Genetics and the Benioff Children’s Hospital at the University of California, San Francisco (UCSF) that evaluated the ability of Bionano’s optical genome mapping technology and another genome analysis method to diagnose children with genetic conditions who previously went undiagnosed by the standard of care methods alone. Of the 50 children in the study, the optical genome mapping results were sufficient to definitively diagnose 6 patients (or 12%) and, for another 10 patients (or 20%), the Bionano data revealed candidate pathogenic variants. Upon further analysis, it is expected that an additional 3 patients could be diagnosed with the Bionano data, bringing the total of definitively diagnosed patients to 9 (or 18%).
Erik Holmlin, Ph.D., CEO of Bionano Genomics commented, “Increasing the number of patients who receive a definitive molecular diagnosis is the driving force behind much of the development of new diagnostic technologies. Every major change in medical guidelines connected to introducing novel methods has been driven by the ability of new methods to diagnose more patients than the previously existing standard of care. This study by the UCSF team shows that Bionano’s optical genome mapping can potentially bring another such leap to the clinic by diagnosing many more patients than what existing chromosomal microarray (CMA) and whole exome sequencing (WES) can. Several studies released this year have shown that Saphyr can detect all clinically relevant variants identified by karyotyping, microarray and FISH in both leukemias and genetic disease cases. This UCSF study now shows in the largest cohort analyzed to date that Bionano’s optical genome mapping diagnoses more patients than the traditional methods. We believe the increase in diagnosis over conventional methods can be a significant factor in Saphyr gaining widespread adoption as a clinical tool for genetic disease diagnosis and next-generation cytogenomics.”
As described in the publication, the UCSF team performed full genome analysis by combining optical genome mapping with Bionano technology and linked-read sequencing on 50 undiagnosed patients with a variety of rare genetic diseases and their parents to determine if this full genome analysis method could help solve cases that had not been diagnosed with previous testing. Of the 50 cases, 42 were previously analyzed by CMA, the first tier medical test for genetic disease cases, and 23 had previously been analyzed with commercial trio whole exome sequencing, and no pathogenic or likely pathogenic variants were identified by these methods.
Bionano’s optical genome mapping technology identified a number of pathogenic variants unidentified by CMA and undetectable by WES, including duplications and deletions that were too small to be identified by CMA, or occurred in regions of the genome not typically covered by CMA or WES. Of the additional 7 patients with variations considered to be candidates for pathogenic variants, the findings included deletions, duplications, and inversions. Before concluding that these variants are sufficient to diagnose the patients, further analysis is required since these variants had not previously been reported in patients with similar disease.
Recent BNGO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/13/2024 08:15:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/13/2024 08:11:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 12:00:18 PM
- Bionano to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference • GlobeNewswire Inc. • 09/04/2024 12:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 08/21/2024 09:00:07 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/21/2024 08:59:15 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/13/2024 04:15:09 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/12/2024 09:19:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 08:14:22 PM
- Bionano Reports Second Quarter 2024 Results and Highlights Recent Business Progress • GlobeNewswire Inc. • 08/07/2024 08:01:00 PM
- Bionano Announces Presentation of Optical Genome Mapping Utility Across Cancer Research Applications at the Cancer Genomics Consortium (CGC) 2024 Annual Meeting • GlobeNewswire Inc. • 08/01/2024 12:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/31/2024 08:21:38 PM
- Bionano to Present at the Canaccord Genuity 44th Annual Growth Conference • GlobeNewswire Inc. • 07/31/2024 08:01:00 PM
- Bionano to Report Second Quarter 2024 Financial Results and Host a Conference Call and Webcast on August 7, 2024 • GlobeNewswire Inc. • 07/31/2024 12:00:00 PM
- Bionano Announces Publication of First Multi-Site Study to Analyze the Utility of OGM in Multiple Myeloma • GlobeNewswire Inc. • 07/23/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2024 08:17:58 PM
- Bionano Announces Closing of up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 07/08/2024 09:25:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 10:16:32 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/08/2024 10:15:27 AM
- Bionano Announces up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 07/05/2024 12:00:00 PM
- Bionano Announces Presentation of OGM Utility Across Stem Cell Therapy Applications at the International Society for Stem Cell Research (ISSCR) Annual Meeting • GlobeNewswire Inc. • 07/02/2024 12:00:00 PM
- Bionano Announces Software Marketing Agreement with Revvity for Newborn Sequencing Research • GlobeNewswire Inc. • 06/20/2024 12:00:00 PM
- Bionano Laboratories Announces New Category I CPT Code for OGM Use in Hematological Malignancy Analysis • GlobeNewswire Inc. • 06/17/2024 08:05:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 06/10/2024 09:12:01 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM